secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2026-08-05T11:04:39+00:00
Accession:  0001689375-26-000052
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada reports Q2 net loss of $42.8M; cash $223M; multiple clinical data readouts ahead
--------------------------------------------------------------------------------

- Net loss of $42.8M in Q2 2026, roughly flat vs $43.1M in Q2 2025; collaboration revenue $0.9M.
- Cash, equivalents and marketable securities $223.0M as of June 30, 2026, down from $295.7M at Dec 31, 2025; runway into Q3 2027.
- ELEVATE-44-201 Cohort 1 open-label data expected by year-end 2026; Cohort 2 data in Q1 2027.
- ELEVATE-45-201 Cohort 1 data expected October 2026; Cohort 2 dosing at 10 mg/kg ongoing with data in H1 2027.
- Vertex to report VX-670 Phase 1/2 data in DM1 in H2 2026; Entrada advancing preclinical ocular candidate ENTR-801 for USH2A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/0001689375-26-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937526000052/trda-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001689375-26-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer